Skip to Content

Join the 'Axumin' group to help and get support from people like you.

Axumin News

FDA Approves Axumin (fluciclovine F 18) Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer

Posted 1 Jun 2016 by

May 27, 2016 – The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels following prior treatment. Prostate cancer is the second leading cause of death from cancer in U.S. men. In patients with suspected cancer recurrence after primary treatment, accurate staging is an important objective in improving management and outcomes. “Imaging tests are not able to determine the location of the recurrent prostate cancer when the PSA is at very low levels,” said Libero Marzella, M.D., Ph.D., director of the Division of Medical Imaging Products in the FDA’s Center for Drug Evaluation and Research. “Axumin is shown to provide another accurate imaging approach for these patient ... Read more

Related support groups: Prostate Cancer, Diagnosis and Investigation, Positron Emission Tomography Imaging, Fluciclovine F 18, Axumin

Ask a Question

Further Information

Related Condition Support Groups

Diagnosis and Investigation, Positron Emission Tomography Imaging

Axumin Patient Information at